Core Viewpoint - DBV Technologies has been admitted to the CAC Mid 60 and SBF 120 Indices, reflecting recognition of its progress in the biopharmaceutical sector and aiming to enhance visibility among investors as it prepares for commercialization [1][2]. Group 1: Company Overview - DBV Technologies is a late-stage biopharmaceutical company focused on developing treatment options for food allergies and other immunologic conditions with significant unmet medical needs [3]. - The company is investigating the use of its proprietary VIASKIN® patch technology, which aims to address food allergies through epicutaneous immunotherapy (EPIT) [3]. - DBV Technologies is committed to transforming the care of individuals with food allergies, with ongoing clinical trials for its VIASKIN Peanut product targeting peanut allergic toddlers and children [3]. Group 2: Market Indices Information - The CAC Mid 60 Index tracks the 60 most actively traded mid-cap French companies, while the SBF 120 Index includes all companies in the CAC Large 60 and CAC Mid 60 Indices [2]. - Inclusion in these indices is expected to increase DBV Technologies' visibility among the French and broader European investment communities [2].

Core Insights - DBV Technologies has appointed James Briggs as Chief Human Resources Officer, succeeding Caroline Daniere, to lead the company's transition from a development-stage biotechnology firm to a potential commercial organization [1][2] - James Briggs brings extensive experience in human capital strategy and organizational transformation, having previously served as a Partner at East Bay Human Capital and held executive roles at MNG Health, Ciox Health, and Ikaria Inc. [2] - The company is focused on developing treatment options for food allergies using its proprietary VIASKIN® patch technology, which aims to modify the immune response to allergens through epicutaneous immunotherapy [4] Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company headquartered in Châtillon, France, with operations in North America [5] - The company is currently conducting clinical trials for its VIASKIN Peanut product aimed at peanut allergic toddlers and children [4] - DBV Technologies is committed to transforming the care of individuals with food allergies, addressing a significant unmet medical need [4]

Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatment options for food allergies and other immunologic conditions with significant unmet medical needs [3][4] - The company is headquartered in Châtillon, France, with North American operations in Warren, NJ [4] Technology and Treatment Approach - DBV Technologies is investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by hypersensitive immune reactions [3] - The VIASKIN® patch is designed to introduce microgram amounts of biologically active compounds to the immune system through intact skin, utilizing epicutaneous immunotherapy (EPIT™) [3] - EPIT™ aims to modify an individual's underlying allergy by re-educating the immune system to become desensitized to allergens, leveraging the skin's immune tolerizing properties [3] Clinical Trials and Focus Areas - The company is currently conducting ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (ages 1 to 3) and children (ages 4 to 7) [3]